List of Excipients in Branded Drug PREDNISONE TABLETS, USP, 5 MG

Generic Drugs Containing PREDNISONE TABLETS, USP, 5 MG

Company	Ingredient	NDC	Excipient
Granulation Technology Inc	prednisone	63561-0120	CELLULOSE, MICROCRYSTALLINE
Granulation Technology Inc	prednisone	63561-0120	LACTOSE MONOHYDRATE
Granulation Technology Inc	prednisone	63561-0120	MAGNESIUM STEARATE
Granulation Technology Inc	prednisone	63561-0120	SILICON DIOXIDE
Granulation Technology Inc	prednisone	63561-0120	SODIUM STARCH GLYCOLATE TYPE A POTATO
Granulation Technology Inc	prednisone	63561-0120	STARCH, CORN

What are the Most Frequently-Used Excipients in PREDNISONE TABLETS, USP, 5 MG?

# Of NDCs	Excipient
7	CELLULOSE, MICROCRYSTALLINE
7	LACTOSE MONOHYDRATE
7	MAGNESIUM STEARATE
7	SILICON DIOXIDE
7	SODIUM STARCH GLYCOLATE TYPE A POTATO
7	STARCH, CORN

Prednisone Tablets USP 5 mg: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 16, 2026

Prednisone tablets USP 5 mg are a mature, multisource immediate-release generic product with limited patent protection and high potential for operational differentiation. The commercial opportunity is not a novel active ingredient or exclusivity position. It is a reliable, low-cost tablet with superior manufacturability, supply continuity, patient acceptability, packaging, and targeted excipient selection.

The strongest formulation strategy is a small, robust, scored tablet that uses widely accepted excipients, minimizes supply-chain risk, supports dose splitting, and avoids unnecessary colors or allergen concerns. Specialty opportunities include lactose-free, dye-free, low-swallowing-burden, pediatric-compatible, and hospital-packaged versions.

What is prednisone 5 mg and how is the product regulated?

Prednisone is a synthetic corticosteroid and prodrug that is converted principally to prednisolone in vivo. It is used for inflammatory, autoimmune, allergic, hematologic, respiratory, dermatologic, and other conditions. The 5 mg strength is important because prednisone therapy often involves dose titration, tapering, chronic low-dose treatment, or combination dosing with other strengths.

In the United States, prednisone tablets are generally approved as abbreviated new drug applications under section 505(j) of the Federal Food, Drug, and Cosmetic Act. An ANDA applicant must demonstrate pharmaceutical equivalence and bioequivalence to a reference listed drug, rather than repeat the full clinical efficacy program required for an innovator product (FDA, 2023a).

The product is a conventional oral tablet. Its principal technical requirements are:

Attribute	Commercial implication
Immediate-release tablet	Dissolution and disintegration must be controlled consistently
5 mg low dose	Content uniformity and blend homogeneity are critical
Frequent dose tapering	Scoring and tablet mechanical strength affect usability
Chronic and acute use	Cost, supply reliability, and tolerability influence purchasing
Generic multisource market	Differentiation must come from execution rather than exclusivity
Small-molecule drug	Biosimilar regulation does not apply

Prednisone is not a biologic. Biosimilar competition is therefore irrelevant. Competition arises from generic tablets, different manufacturers, contract manufacturers, private-label suppliers, and, in some treatment settings, prednisolone or methylprednisolone products.

What excipients are used in prednisone 5 mg tablets?

There is no single universal excipient formula for prednisone tablets USP 5 mg. Each approved manufacturer may use a different composition, provided the product meets applicable quality, safety, bioequivalence, and labeling requirements. FDA-approved labels commonly identify combinations of fillers, binders, disintegrants, lubricants, and, in some products, colorants.

Typical excipient categories include:

Excipient function	Common examples	Role in prednisone 5 mg
Diluent or filler	Lactose monohydrate, microcrystalline cellulose, starch	Provides tablet mass and improves compression
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet cohesion
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Promotes tablet breakup after administration
Lubricant	Magnesium stearate, stearic acid	Reduces sticking and ejection force
Glidant	Colloidal silicon dioxide	Improves powder flow
Colorant	Approved FD&C or D&C pigments	Supports product identification
Film coat	Hypromellose, polyethylene glycol, titanium dioxide, talc	Improves appearance, handling, and swallowability

The exact inactive ingredients must be taken from the target product’s current prescribing information and DailyMed record. DailyMed labels show that different prednisone products can have materially different inactive-ingredient profiles, even when they share the same active ingredient, strength, and dosage form (National Library of Medicine, 2024).

How should the excipient platform be selected?

A standard formulation can use lactose, starch or cellulose, a superdisintegrant, and magnesium stearate. This is usually the lowest-risk path for a conventional ANDA because the materials are established in oral solid dosage forms and are widely represented in FDA’s Inactive Ingredient Database.

The main selection criteria should be:

1. Blend uniformity at a 5 mg drug load.
2. Acceptable dissolution across relevant pH conditions.
3. Low sensitivity to lubricant overmixing.
4. Adequate hardness without delayed disintegration.
5. Reliable tablet ejection and low punch sticking.
6. Stable assay and degradation profile.
7. Access to at least two qualified suppliers.
8. Compatibility with direct compression or a simple granulation process.
9. Acceptable impurity and elemental impurity profiles.
10. Commercial fit with the intended patient and procurement segment.

Low-dose prednisone creates a content-uniformity challenge. The active ingredient must be distributed evenly through the powder blend. A formulation that is inexpensive but sensitive to segregation can create manufacturing losses, out-of-specification risk, and regulatory exposure.

What formulation opportunities exist for prednisone 5 mg?

Can a lactose-free prednisone tablet create a commercial niche?

Yes. A lactose-free product can address patients who avoid lactose, hospitals with formulary preferences, and buyers seeking simplified excipient labeling. The opportunity is limited by the fact that lactose intolerance does not necessarily make small quantities of tablet lactose clinically significant. The commercial value depends on transparent labeling and reliable positioning rather than a broad clinical claim.

Microcrystalline cellulose, mannitol, calcium phosphate, or starch-based systems can replace lactose. Each alternative changes compressibility, tablet weight, mouthfeel, and dissolution. A lactose-free product should not be marketed as clinically superior without supporting evidence.

Is a dye-free prednisone tablet commercially attractive?

A dye-free tablet can reduce concerns among patients and caregivers who seek to avoid colorants. It also simplifies sourcing and may reduce the risk of colorant-specific supply disruptions. The principal disadvantage is a less distinctive tablet appearance, which can increase medication-identification risk if shape, imprint, and packaging are not carefully designed.

A white or off-white scored tablet with a strong imprint can be commercially viable for retail, hospital, and mail-order channels.

Can a low-swallowing-burden or pediatric formulation compete?

Prednisone is used in pediatric practice, but a conventional 5 mg tablet may not be suitable for all children. A smaller tablet, improved score design, or dispersible product could create a differentiated product. The formulation must preserve dose accuracy after splitting or dispersion.

An oral solution or concentrated liquid may compete for patients who cannot swallow tablets. That product would have different excipient, preservative, palatability, stability, and packaging requirements. A tablet manufacturer should treat the liquid as a separate product platform rather than a simple line extension.

Potential excipient approaches include:

• Mannitol-based tablets for improved mouthfeel.
• Crospovidone or croscarmellose for rapid breakup.
• Lower tablet mass for easier swallowing.
• A clean-label, dye-free composition for pediatric and caregiver acceptance.
• Packaging with clear dose-splitting instructions.
• Unit-dose blisters for hospital and ambulatory-care settings.

Are orally disintegrating prednisone tablets a strong opportunity?

The opportunity exists but is narrower than the standard tablet market. An orally disintegrating tablet could address dysphagia, emergency use, and selected pediatric patients. It would require careful control of taste, friability, moisture sensitivity, packaging, and dose uniformity.

The regulatory burden may be higher than for a conventional tablet because the product’s performance depends on rapid disintegration and patient acceptability. A commercial sponsor would need evidence that the differentiated dosage form justifies added development and packaging costs.

What patents protect prednisone tablets USP 5 mg?

Prednisone 5 mg tablets are generally a mature generic product without an obvious active-ingredient patent barrier. The original compound and conventional tablet technology have long historical use. Current commercial risk is more likely to arise from manufacturing quality, supply interruption, or competitor pricing than from a blocking composition-of-matter patent.

Patent analysis should separate four categories:

Patent category	Relevance to conventional prednisone 5 mg
Composition-of-matter patents	No practical barrier for a mature generic active ingredient
Formulation patents	Potentially relevant only if a specific protected formulation is copied
Method-of-use patents	May affect labeling and Paragraph IV analysis, but many uses are established
Manufacturing patents	Could matter if a specific process is copied, although alternative processes are usually available

The Orange Book determines whether FDA has listed patents for a particular reference product. The relevant analysis must be performed against the specific reference listed drug, NDA, dosage form, and current Orange Book edition. A general statement that prednisone is “off patent” does not eliminate the need to review listed patents, pediatric exclusivity, 30-month stays, and any litigation history (FDA, 2024a).

When does prednisone 5 mg lose exclusivity?

For conventional generic prednisone 5 mg, market entry is generally governed by ANDA approval and any applicable listed patent or regulatory exclusivity. The product does not have the exclusivity profile associated with a recently approved innovative drug.

Potential regulatory barriers include:

• A listed patent on the reference product.
• A Paragraph IV certification and resulting litigation.
• 30-month stay protection if the reference sponsor sues within the statutory period.
• Orphan-drug exclusivity for a specific indication, if applicable.
• Pediatric exclusivity attached to qualifying listed patents.
• REMS or other product-specific requirements, although these are not typically central to standard prednisone tablets.

Because prednisone is a mature corticosteroid, the most likely generic launch scenario is approval based on bioequivalence without a prolonged patent delay. The commercial launch date still depends on the target reference product, application review, facility readiness, inspection status, and supply release.

What is the Orange Book status of prednisone tablets?

The Orange Book identifies approved drug products, reference listed drugs, therapeutic-equivalence evaluations, and listed patent or exclusivity information. Prednisone tablets are typically represented by multiple approved generic products with “AB” therapeutic-equivalence ratings where the relevant FDA criteria are satisfied.

An AB rating supports substitution under applicable state pharmacy laws, but substitution rules vary by jurisdiction. The product’s actual competitive position depends on:

• Whether it is rated therapeutically equivalent to the reference listed drug.
• Whether all marketed strengths are approved and available.
• Whether the manufacturer has adequate supply.
• Whether the National Drug Code is active and commercially maintained.
• Whether wholesalers and group purchasing organizations list the product.
• Whether the product has a shortage, back-order, or discontinuation history.

The Orange Book is a regulatory reference, not a complete commercial-sales database. It does not by itself establish market share, net price, contract coverage, or channel profitability.

Which companies are challenging prednisone patents?

Prednisone is not normally characterized by a current high-profile Paragraph IV patent challenge landscape comparable to protected products such as inhaled combinations, long-acting injectables, or specialty biologics. Generic manufacturers generally compete through ANDA filings, manufacturing scale, pricing, and distribution.

A meaningful challenge assessment requires reviewing:

1. Orange Book patent listings for the relevant reference NDA.
2. FDA Paragraph IV certifications where publicly available.
3. Federal court dockets under Hatch-Waxman provisions.
4. ANDA approvals and tentative approvals.
5. Product discontinuation and shortage records.
6. Current commercial listings by strength and package size.

No biosimilar developers are relevant because prednisone is a small molecule. The competitive set includes generic oral corticosteroid manufacturers and therapeutic alternatives such as prednisolone, dexamethasone, and methylprednisolone.

What patent litigation and settlement risks affect prednisone?

The litigation risk for a standard prednisone 5 mg tablet is generally lower than for newer specialty products. The main legal risks are product-specific rather than molecule-wide.

Potential disputes may involve:

• Infringement of an unexpired formulation patent.
• Process-patent claims concerning granulation, coating, or impurity control.
• Labeling disputes involving patented methods of use.
• Trade dress, tablet appearance, or packaging claims.
• ANDA certification errors.
• Manufacturing-site or supplier disclosures in regulatory submissions.

A Paragraph IV settlement could delay launch, permit an agreed entry date, or include a license or supply arrangement. However, a settlement analysis should not be inferred from the existence of multiple generic products. Marketed generics may have entered after patent expiry, after a non-infringement position, or under a private agreement that is not commercially material.

How strong is the patent estate for prednisone 5 mg?

The patent estate is weak for the conventional active ingredient and standard immediate-release tablet. A sponsor seeking durable differentiation would need to create a defensible product feature, such as:

• A novel dose-splitting mechanism.
• A protected modified-release profile.
• A validated pediatric dispersible dosage form.
• A specialized taste-masked formulation.
• A combination product with a distinct clinical rationale.
• A manufacturing process that produces a measurable quality advantage.
• A delivery system that solves a defined adherence or swallowing problem.

Even then, patent protection would need to be evaluated against obviousness, enablement, written description, freedom to operate, and the ability of generic competitors to design around the claims.

An excipient substitution alone usually has limited patent value. A patent application directed only to replacing lactose with microcrystalline cellulose may face substantial obviousness risk unless it produces an unexpected, measurable result or is linked to a technically distinctive product profile.

What manufacturing and excipient barriers affect commercial entry?

The main barriers are executional:

Content uniformity

The 5 mg strength has a low active-to-excipient ratio. Segregation, poor premix design, and inconsistent granule size can cause assay variability. A premix strategy or controlled granulation process may be preferable to a simple high-speed direct-compression process if blend uniformity is difficult to maintain.

Dissolution control

Prednisone dissolution must remain consistent across batches. Excessive compression force, over-lubrication, hydrophobic excipient selection, or insufficient disintegrant can slow release.

Tablet scoring

A score creates commercial value only if the tablet splits accurately and remains mechanically robust. The sponsor should evaluate split-tablet weight variation, friability, dose uniformity, and user handling.

Supply-chain resilience

The formulation should avoid dependence on a single supplier for lactose, magnesium stearate, colorant, coating polymer, or specialized tooling. Dual sourcing is especially valuable in a low-margin product where a brief interruption can eliminate profitability.

Packaging

Bottles minimize cost. Blisters support unit-dose hospital use, adherence packaging, and product identification but increase packaging expense. Moisture protection should match the selected excipient system and stability profile.

How does prednisone 5 mg compare with competing corticosteroids?

Product	Primary competitive distinction	Commercial implication
Prednisone 5 mg	Low-cost oral prodrug with broad use	Large generic base and dose-tapering demand
Prednisolone	Active metabolite, available in liquid and tablet forms	Stronger pediatric and dysphagia competition
Methylprednisolone	Different potency and dosing conventions	Competes in acute inflammatory treatment
Dexamethasone	Higher potency and longer duration	Not a direct milligram-for-milligram substitute
Hydrocortisone	Shorter-acting corticosteroid	Competes in selected replacement and inflammatory uses

Prednisone’s strongest commercial advantage is familiarity and low cost. Its principal weakness is formulation flexibility. Prednisolone liquids and alternative corticosteroids may be preferred when precise pediatric dosing, swallowing ease, or clinical pharmacology is prioritized.

What commercial opportunities exist for prednisone 5 mg?

The best opportunities are segmented rather than molecule-wide.

Retail generic supply

A standard tablet can compete through low manufacturing cost, high fill rates, multiple package sizes, and reliable wholesaler availability. The product is suited to high-volume commodity procurement, but margins can be compressed by multiple approved suppliers.

Hospital and institutional channels

Unit-dose packaging, barcoding, strong tablet identification, and reliable replenishment can support hospital contracts. A dye-free and lactose-free label may help formulary positioning, although procurement decisions usually remain price and supply driven.

Specialty pharmacy and chronic therapy

Patients receiving long-term corticosteroid treatment may value consistent availability, clearly scored tablets, and packaging that supports tapering schedules. A manufacturer should avoid unsupported adherence claims, but it can create practical value through pack design and labeling clarity.

Pediatric and dysphagia niches

A smaller tablet, dispersible format, or palatable product can command a higher price if it solves a genuine administration problem. These products face more development and quality-control requirements than a standard tablet.

Contract manufacturing and private label

Prednisone 5 mg is compatible with private-label and contract-manufacturing models because the product is standardized, stable relative to many specialty products, and distributed through multiple channels. Capacity, inspection readiness, and quality history may be more valuable than proprietary formulation claims.

Geographic expansion

The product may have demand in markets where corticosteroids are widely prescribed and generic substitution is established. Geographic expansion requires country-specific review of excipient permissions, tablet scoring standards, labeling, pharmacopoeial requirements, bioequivalence rules, and permitted claims. USP compliance alone does not establish approval in Europe, Canada, Latin America, or Asia.

Key Takeaways

• Prednisone tablets USP 5 mg are a mature generic opportunity with limited conventional patent risk.
• Excipient selection should prioritize content uniformity, dissolution, compression robustness, and supply continuity.
• Lactose-free, dye-free, smaller, scored, dispersible, and unit-dose variants offer the clearest differentiation.
• The standard product is usually regulated through the ANDA pathway and competes on therapeutic equivalence, price, availability, and quality.
• Biosimilar risk does not apply because prednisone is a small molecule.
• Formulation patents may protect a differentiated delivery system, but ordinary excipient substitution is unlikely to create strong exclusivity.
• The strongest commercial strategy is a reliable base formulation paired with targeted packaging or administration improvements.
• Current Orange Book patents, ANDA status, therapeutic-equivalence ratings, and litigation must be assessed against the specific reference listed drug.

FAQs About Prednisone 5 mg Excipient and Commercial Strategy

Is lactose commonly used in prednisone 5 mg tablets?

Lactose monohydrate is a common tablet diluent and may appear in prednisone products, but the exact composition varies by manufacturer. A lactose-free version can be developed with cellulose, starch, mannitol, or another suitable filler.

Does prednisone 5 mg need a scored tablet?

A score is commercially useful because prednisone therapy often involves tapering and dose adjustment. The manufacturer must demonstrate acceptable split-tablet performance if the score is intended for dose subdivision.

Can a manufacturer patent a new prednisone excipient formulation?

A patent may be possible if the formulation has a novel, non-obvious composition or produces an unexpected technical result. A routine substitution of one conventional filler for another generally provides limited patent strength.

Is prednisone 5 mg eligible for automatic pharmacy substitution?

Substitution depends on the FDA therapeutic-equivalence rating and applicable state law. An AB-rated generic is generally positioned for substitution, but pharmacy rules and payer practices vary.

What is the highest-value product extension for prednisone 5 mg?

A standard low-cost tablet remains the broadest opportunity. A pediatric-friendly or dysphagia-oriented product may offer higher unit value, but it requires stronger evidence for dose accuracy, disintegration, taste, packaging, and user handling.

References

1. Food and Drug Administration. (2023a). Abbreviated new drug application process. U.S. Department of Health and Human Services. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda

2. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov/scripts/cder/ob/

3. Food and Drug Administration. (n.d.). Inactive ingredient database. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

4. National Library of Medicine. (2024). DailyMed: Prednisone tablet labeling. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/

5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary (USP-NF). United States Pharmacopeial Convention.